GlassScriptPhysician profile
Jared M Braunstein
NPI 1295994762
$9,147.61
in general payments reported to CMS, 2019-2025
24 companies · $794 in 2025
The $794 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $125 · 2021: $622 · 2022: $1,046 · 2023: $3,091 · 2024: $1,822 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,688 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,687.89 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $1,094.84 | 2023-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Gilead Sciences, INC. | $1,031.47 | 2019-2023 | Descovy |
| Astrazeneca Pharmaceuticals LP | $982.80 | 2023-2025 | Breztri, Airsupra |
| Amgen INC. | $914.89 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $764.62 | 2022-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $741.21 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Cequr Corporation | $567.46 | 2023 | Cequr Simplicity |
| Intuity Medical INC | $499.07 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Xeris Pharmaceuticals, INC. | $404.78 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Intercept Pharmaceuticals, INC. | $380.82 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.41 | 2023-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.28 | 2023-2024 | Xifaxan, Trulance |
| Allergan, INC. | $148.18 | 2019 | |
| Idorsia Pharmaceuticals US INC | $143.67 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $139.83 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Antares Pharma, INC. | $125.00 | 2023 | Xyosted, Tlando |
| Nevro Corp. | $120.53 | 2022 | |
| Amarin Pharma, INC. | $117.43 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.04 | 2022 | |
| Viiv Healthcare Company | $110.06 | 2022 | |
| Amryt Pharma Holdings LTD | $102.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $90.61 | 2019 | |
| Astellas Pharma US INC | $31.54 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Braunstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.